A new analysis being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), finds that around ...

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Learn how emerging technologies are enhancing patient engagement and treatment strategies in everyday practice.

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Despite the approval of second-generation antiobesity medications, metabolic and bariatric surgery (MBS) use among U.S.

CEO Andrew Dudum said the funds will allow the company to grow internationally and invest in artificial intelligence.

GLP1 drugs are changing patients eating and grocery shopping habits - 2 News Oklahoma's Cathy Tatom hears how from a patient, ...

Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated ...

Data from a Swedish clinic suggests that GLP-1 drugs can be effective in managing severe obesity in children, offering a ...

In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...